NOTICE TO INVESTORS: Fate Therapeutics, Inc. Investors Suffering Substantial Losses Have Opportunity to File Class Action – FATE

SAN DIEGO, January 28, 2023 /PRNewswire/ — Robbins Geller Rudmann & Dowd LLP announces that purchasers or acquirers of securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023the two dates included (the “Class Period”) have until March 22, 2023 to seek appointment as lead applicant in the fate therapy class action. Subtitle Hadian vs. Fate Therapeutics, Inc.No. 23-cv-00111 (SD Cal.), the fate therapy The class action accuses Fate Therapeutics and some of its senior executives of violating the Securities Exchange Act of 1934.

If you have suffered substantial losses and wish to act as the lead plaintiff of the fate therapy class action, please provide your information here:

https://www.rgrdlaw.com/cases-fate-therapeutics-inc-class-action-lawsuit-fate.html

You can also contact the lawyer JC Sanchez of Robbins Geller by calling 800/449-4900 or emailing [email protected].

CASE ALLEGATIONS: Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies to treat cancer and immune disorders. At April 2, 2020Fate Therapeutics has announced a collaboration agreement with Janssen Biotech, Inc. (the “Janssen Collaboration Agreement”), pursuant to which Fate Therapeutics has received a $50 million payment and was eligible for future payments that totaled billions of dollars.

The fate therapy the class action alleges that, throughout the class action period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less durable than that that Fate Therapeutics had represented to investors; (ii) therefore, some of the clinical programs, milestone payments and royalty payments associated with the Janssen Collaboration Agreement could not be considered future sources of revenue; and (iii) as a result, Fate Therapeutics had overestimated the impact of the Janssen collaboration agreement on its long-term clinical and commercial profitability.

At January 5, 2023, Fate Therapeutics has announced that it has terminated the Janssen collaboration agreement. Specifically, Fate Therapeutics revealed that it was “unable to match Janssen on its proposal to continue our collaboration, where two product candidates targeting high-value, clinically validated hematology antigens were to enter development. clinic in 2023”. Following the termination, Fate Therapeutics revealed that all licenses and other rights granted under the Janssen Collaboration Agreement would end, it would downsize in 2023, and discontinue several of its killer programs. of natural cells in various cancers. . At this news, Fate Therapeutics’ share price fell more than 61%, hurting investors.

THE PRINCIPAL APPLICANT PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired securities of Fate Therapeutics during the Class Period to seek appointment as lead plaintiff in the fate therapy class action. A principal plaintiff is generally the plaintiff with the greatest financial interest in the relief sought by the putative class that is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members by directing the fate therapy class action. The main plaintiff can select a law firm of his choice to plead fate therapy class action. An investor’s ability to participate in any potential future takeover does not depend on its status as the lead claimant of the fate therapy class action.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The firm is ranked #1 in the most recent ISS Securities Class Action Services Top 50 report for recovering nearly $2 billion for investors in 2021 – more than triple the amount recovered by any other company from the plaintiffs. With 200 attorneys in 9 offices, Robbins Geller is one of the largest plaintiffs firms in the world, and the firm’s attorneys have secured many of the largest securities class action recoveries in history, including the largest securities class action collection never realized – $7.2 billion – in In re Enron Corp. Dry. Litigation Please visit the following page for more information:

https://www.rgrdlaw.com/services-litige-securities-fraud.html

Lawyer advertisement.
Past results do not guarantee future results.
Services can be performed by attorneys in any of our offices.

SOURCE Robbins Geller Rudman & Dowd LLP